luspatercept
luspatercept: sourced relationships with 1 company · 15 clinical trials tracked.
luspatercept evidence translation
What we can confirm
15 tracked trials
What it means
What to watch
Prepared research question
How could luspatercept → CELG affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| CELGENE CORP /DE/ (CELG) low-to-intermediate risk myelodysplastic syndromes (MDS), tr… | Phase 3 |
Clinical Trial Registry Records (15)showing 10 most recent
A Prospective, Multicenter, Non-Interventional Study Assessing First-line Luspatercept in Anemic Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Neoplasms Requiring Red Blood Cell Transfusions
Primary endpoint: Percentage of participants achieving red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeks
A Multicenter Phase 2 Study of Luspatercept in Patients With Anemia Due to Chronic Kidney Disease
Primary endpoint: Hemoglobin (HB) improvement
REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study
Primary endpoint: Change in transfusion burden
Observational Retrospective Study on Incidence, First-line Treatment Patterns, and Clinical Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain Using the BIG-PAC® Database
Primary endpoint: Incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes
Primary endpoint: Mean Rate of Red Blood Cell Transfusion Independence
Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance
Primary endpoint: Number of patients achieving cytopenia responses as defined by HI-E, HI-P, HI-N, mHI-E responses
Treatment Patterns and Effectiveness of Luspatercept in the Real World
Primary endpoint: Participant baseline demographics
Luspatercept Treatment Patterns and Outcomes Among ESA-Naïve Patients With Lower-Risk MDS - A Retrospective Medical Record Review in the United States
Primary endpoint: Participant baseline demographics
Real World Use of Luspatercept in Lower Risk Myelodysplastic Syndromes and Beta-thalassemia Patients
Primary endpoint: Participant age
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
Primary endpoint: Number of participants with lower-risk non-transfusion dependent myelodysplastic syndromes (NTD-MDS) who converted to Transfusion Dependence (TD) during any continuous 16-week interval within the 96-week treatment period
Frequently asked questions
Which companies have sourced relationships with luspatercept?
luspatercept has dated SEC/FDA relationship records for CELGENE CORP /DE/.
How many clinical trials involve luspatercept?
BioSniper tracks 15 clinical trials involving luspatercept.